Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: Modelization using a standardized set of response criteria

Prostate

Volumn 67, Issue 14, 2007, Pages 1543-1549

  Banu, Eugeniu ^a   Banu, Adela ^a   Medioni, Jacques ^a   Levy, Eric ^a   Thiounn, Nicolas ^c   Mejean, Arnaud ^c   Andrieu, Jean Marie ^a   Oudard, Stephane ^a,b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Predictive factor; Prostate cancer; PSA half life; Survival

Indexed keywords

ANTIANDROGEN; CAPECITABINE; CORTICOSTEROID; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; GONADORELIN DERIVATIVE; MITOXANTRONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 35148863036     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20627     Document Type: Article

References (28)

1. Vollmer RT, Montana GS. The dynamics of prostate-specific antigen after definitive radiation therapy for prostate cancer. Clin Cancer Res 1999;5(12):4119-4125.
2. Sissons GR, Clements R, Peeling WB, Penney MD. Can serum prostate-specific antigen replace bone scintigraphy in the follow-up of metastatic prostatic cancer? Br J Radiol 1992;65(778):861-864.
3. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17(11):3461-3467.
4. Oudard S, Banu E, Banu A, Scotte F, Levy E, Le Maignan C, Andrieu JM. Prostate-specific antigen half-time (PSAHT) as a predictor of survival for hormone-refractory prostate cancer (HRPC): A standardized set of response criteria. Proc Am Soc Clin Oncol 2003;22(in press):416.
5. Bjork T, Schalken J, Wittjes W, Ljungberg B, Lilja H. Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues. Prostate 2001;47(1):14-20.
6. Atkinson AJ, Kushner W. Clinical pharmacokinetics. Annu Rev Pharmacol Toxicol 1979;19:105-127.
7. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35(1):1-39.
8. Aickin M, Gensler H. Adjusting for multiple testing when reporting research results: The Bonferroni vs Holm methods. Am J Public Health 1996;86(5):726-728.
9. Dowling AJ, Czaykowski PM, Krahn MD, Moore MJ, Tannock IF. Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: Prognostic factors and generalizability of a multicenter trial to clinical practice. J Urol 2000;163(5):1481-1485.
10. Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotte F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2005;23(15):3343-3351.
11. Woynarowska BAL, Munoz RM, Bushong P, Waters SJ. Changes in prostate-specific antigen (PSA) level correlate with growth inhibition of prostate cancer cells treated in vitro with a novel anticancer drug, irofulven. Invest New Drugs 2001;19(4):283-291.
12. Carducci MA, DeWeese TL, Nelson JB. Prostate-specific antigen and other markers of therapeutic response. Urol Clin North Am 1999;26(2):291-302, viii.
13. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993;11(4):607-615.
14. Petrylak DP, Tangen CM, Hussein MH, Lara PN, Jr., Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-1520.
15. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-1512.
16. Scher HI, Mazumdar M, Kelly WK. Clinical trials in relapsed prostate cancer: Defining the target. J Natl Cancer Inst 1996;88(22):1623-1634.
17. Dawson NA. Response criteria in prostatic carcinoma. Semin Oncol 1999;26(2):174-184.
18. Mahler C, Denis LJ. Hormone refractory disease. Semin Surg Oncol 1995;11(1):77-83.
19. Small EJ, McMillan A, Meyer M, Chen L, Slichenmyer WJ, Lenehan PF, Eisenberger M. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: Association with progression-free survival, pain end points, and survival. J Clin Oncol 2001;19(5):1304-1311.
20. Chautard D, Cellier P, Dalifard I, Pabot du Chatelard P, Chaussis F, Vielle B, Soret JY, Passagot J, Courte C, Daver A. Biochemical monitoring of prostate cancer treated exclusively by radiotherapy: Prognostic value of pretreatment PSA, PSA nadir and PSA half-life. Prog Urol 2002;12(3):421-428.
21. Di Federico G, Zezza A, Nicolai M, Lombardi G, Cipollone G, Iantorno R, Boni R, Tenaglia R. Half-life of blood PSA after radical prostatectomy. Correlations with pathological stage and clinical course of the disease. Arch Ital Urol Androl 1997;69(Suppl 1):97-100.
22. Choo R, DeBoer G, Klotz L, Danjoux C, Morton GC, Rakovitch E, Fleshner N, Bunting P, Kapusta L, Hruby G. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 2001;50(3):615-620.
23. Hanks GE, D'Amico A, Epstein BE, Schultheiss TE. Prostatic-specific antigen doubling times in patients with prostate cancer: A potentially useful reflection of tumor doubling time. Int J Radiat Oncol Biol Phys 1993;27(1):125-127.
24. Loberg RD, Fielhauer JR, Pienta BA, Dresden S, Christmas P, Kalikin LM, Olson KB, Pienta KJ. Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer. Urology 2003;62 (Suppl 1):128-133.
25. Kubota Y, Yanai H, Sasagawa I, Suzuki H, Nakada T, Sugano O. Prostate-specific antigen in patients with relapsed prostate cancer following endocrine treatment. Int Urol Nephrol 1996;28(3):349-355.
26. Clamp A, Jayson GC. Weekly platinum chemotherapy for recurrent ovarian cancer. Br J Cancer 2002;86(1):2-4.
27. Ayash LJ, Clarke M, Silver SM, Braun T, Uberti J, Ratanatharathorn V, Reynolds C, Ferrara J, Broun ER, Adams PT. Double dose-intensive chemotherapy with autologous stem cell support for relapsed and refractory testicular cancer: The University of Michigan experience and literature review. Bone Marrow Transplant 2001;27(9):939-947.
28. Willemse PH, Aalders JG, de Bruyn HW, Mulder NH, Sleijfer DT, de Vries EG. CA-125 in ovarian cancer: Relation between half-life, doubling time and survival. Eur J Cancer 1991;27(8):993-995.